Background--Cholesterol efflux from cells to apolipoprotein A-I (apoA-I) acceptors via the ATP-binding cassette transporters ABCA1 and ABCG1 is thought to be central in the antiatherogenic mechanism. MicroRNA (miR)-33 is known to target ABCA1 and ABCG1 in vivo.
A lthough the lowering of LDL cholesterol (LDL-C) with the use of statins has revolutionized the treatment of atherosclerotic cardiovascular disease, statins can only reduce the risk of cardiovascular events by up to 50% depending on the disease status and the amount of statin used, which still leaves a large burden of residual disease risk. [1] [2] [3] Recent studies have shown that HDL cholesterol (HDL-C) levels under statin treatment remain an independent predictor of the risk of cardiovascular events in patients who have been treated with statins to lower LDL-C levels 4 and that HDL-C levels at baseline are a strong predictor of 12-month morbidity and mortality from cardiovascular events in patients on statins with low LDL-C levels undergoing stent placement for acute coronary syndromes. 5 Thus, clinical and epidemiological studies have consistently shown that there is an inverse relationship between HDL-C concentration and cardiovascular risk. In fact, a 1 mg/dL (0.026 mmol/L) increment in HDL-C levels was associated with a significant decrease in the risk of coronary heart disease of 2% in men and 3% in women. 6 All these data led us to the idea that the development of therapies that raise HDL-C is necessary to reduce cardiovascular diseases in the midst of the "statin era" in the management of atherosclerosis. Transgenic mice that overexpress apoA-I and the infusion of apoA-I/phospholipid complexes in humans are associated with reduced progression or regression of atherosclerosis. [7] [8] [9] These observations have suggested that HDL-C-raising therapies might be an effective way to reduce the residual risk of cardiovascular diseases in patients who are being treated with current therapies.
The identification of ATP-binding cassette transporter A1 (ABCA1) as a rate-limiting factor in HDL-C biogenesis suggested that increased ABCA1 activity could inhibit atherosclerosis. Studies in mice in which the Abca1 locus is either deleted or overexpressed generally have supported the hypothesis that ABCA1 significantly prevents atherosclerosis by maintaining circulating HDL-C levels and cellular cholesterol efflux. [10] [11] [12] [13] Tissue-specific knockouts of the Abca1 locus were generated and revealed that liver and macrophage ABCA1 both play roles in preventing atherosclerosis. 14 ABCA1
modulates cell-surface cholesterol levels, inhibits its partitioning into lipid rafts, and decreases the responsiveness of inflammatory signals from innate immune receptors. Moreover, ABCA1 has been reported to act directly as an antiinflammatory receptor independent of its lipid transport activities. 15 Therefore, augmentation of the function of ABCA1 might be a beneficial therapeutic approach. MicroRNA (miR) is small, nonprotein-coding RNA that binds to specific mRNA and inhibits translation or promotes mRNA degradation. Recent reports, including ours, have indicated that miR-33 controls cholesterol homeostasis based on knockdown experiments using antisense technology. [16] [17] [18] Moreover, antisense inhibition of miR-33 resulted in a regression of the atherosclerotic plaque volume in LDLreceptor-deficient mice. 19 Antisense inhibition of miRNA function is an important tool for elucidating miRNA biology and evaluating its therapeutic potential. However, to determine the organ-/cell-type-specific function of miRNA over the long term in vivo, studies on miRNA-deficient mice and the analysis of specific organ/cell types from these mice are needed, especially for the development of therapeutic strategies for chronic diseases, such as atherosclerosis, dyslipidemia, and metabolic syndrome.
In the present study, we crossed miR-33-deficient mice (miR-33 À/À ) with apoE-deficient mice (Apoe À/À ) to examine the impact of miR-33 deletion on the progression of atherosclerosis and demonstrated that genetic loss of miR-33 raises circulating HDL-C and decreases atherosclerotic plaque size. Furthermore, loss of leukocyte miR-33 significantly reduced the lipid content in atherosclerotic plaque. Our results indicate that miR-33 deficiency raises both HDL-C and macrophage cholesterol efflux and strongly suggest that miR-33 should be considered as a potential target for the prevention of atherosclerosis. However, some of the previously validated targets of miR-33, such as RIP140 and CROT, were upregulated in miR-33 À/À Apoe À/À mice compared with miR-33 +/+ Apoe À/À mice, whereas CPT1a and AMPKa were not. Moreover, the effect of miR-33 deletion in macrophages is not as simple as the shift from the M1 to M2 phenotype reported previously. 19 Thus, to establish that the silencing of miRNA is a therapeutic strategy for the treatment of humans, further detailed experiments are required.
Methods Cell Culture and Reagents
Peritoneal macrophages were obtained from the peritoneal cavity of mice 4 days after intraperitoneal injection of 
Generation of MiR-33 and ApoE Double-Knockout Mice
To obtain miR-33 and apoE double-knockout mice (miR-33
À/À mice were mated with Apoe À/À mice, which were backcrossed to C57BL/6 mice for 10 generations. [20] [21] [22] Because both knockout mice had a BL/6 background, 
Serum Lipid Profiling
After mice were fasted for 4 to 6 hours, blood was obtained from the inferior vena cava of anesthetized mice, and serum was separated by centrifugation at 4°C and stored at À80°C. Serum lipoproteins were measured by standard methods (Accelerator selective detergent method using a Hitachi 7180 Auto Analyzer; Nagahama Life Science Laboratory, Nagahama, Japan) and HPLC methods (Sky Light Biotech, Akita, Japan).
Western Blotting
Western blotting was performed using standard procedures as described previously. 23 A total of 20 lg of protein was fractionated using NuPAGE 4% to 12% Bis-Tris gels (Invitrogen) and transferred to a Protran nitrocellulose transfer membrane (Whatman). The membrane was blocked using 19 phosphatebuffered saline (PBS) containing 5% nonfat milk for 1 hour and incubated with the primary antibody (anti-ABCA1, 1:1000; anti-ABCG1, 1:1000; anti-cleaved caspase-3, 1:500; anti-AMPKa, 1:1000; anti-CROT, 1:100; anti-CPT1a, 1:1000; anti-RIP140, 1:500; anti-b-actin, 1:3000; anti-GAPDH, 1:3000) overnight at 4°C. Following a washing step in PBS-0.05% Tween 20 (0.05% T-PBS), the membrane was incubated with the secondary antibody (anti-rabbit or anti-mouse IgG HRP-linked, 1:2000) for 1 hour at 4°C. The membrane was then washed in 0.05% T-PBS and detected by ECL Western Blotting Detection Reagent (GE Healthcare) using an LAS-1000 system (Fuji Film).
RNA Extraction and Quantitative Real-Time PCR (qRT-PCR)
Total RNA was isolated and purified using TRIzol reagent (Invitrogen), and cDNA was synthesized from 1 lg of total RNA using Transcriptor First Strand cDNA Synthesis Kit (Roche) in accordance with the manufacturer's instructions. For qRT-PCR, specific genes were amplified by 40 cycles using SYBR Green PCR Master Mix (Applied Biosystems). Expression was normalized to the housekeeping gene Actb. Quantitative PCR for MicroRNA
Total RNA was isolated using TRIzol reagent (Invitrogen). MiR-33 was measured in accordance with the TaqMan MicroRNA Assays (Applied Biosystems) protocol, and the products were analyzed using a thermal cycler (ABI Prism7900HT sequence detection system). Samples were normalized by U6 snRNA expression.
Cholesterol Efflux via Mouse ApoB-Depleted Serum
Cholesterol efflux via mouse apoB-depleted serum was measured as described previously. 24, 25 Briefly, J774 cells were plated in 24 multiwell plates (7910 4 cells/well) and labeled for 24 hours using 3 H-cholesterol (2 lCi/mL) in RPMI1640 plus 1% FBS. Cells were incubated in RPMI1640 containing Cpt-cAMP (0.3 mmol/L) and 0.2% BSA for an additional 16 hours to upregulate ABCA1 in J774 cells. Cells were washed and incubated for 4 hours in MEM-HEPES containing 2.8% apoB-depleted serum (equivalent to 2% serum), which was obtained after apoB lipoproteins were removed with PEG. 26 All steps were performed in the presence of acyl-coenzyme A:cholesterol acyltransferase (ACAT) inhibitor (2 lg/mL). Cholesterol efflux was expressed as the percentage of radioactivity released from the cells in the medium relative to the total radioactivity in cells plus medium.
Cholesterol Efflux From Mouse Peritoneal Macrophages
Cellular cholesterol efflux via apoA-I and HDL was determined as described previously. 22 and then switched to a WTD for 12 weeks. At age 24 weeks, mice were euthanized and analyzed. The hematologic chimerism of mice was determined by PCR using genomic DNA from blood, BM, and tail with the PCR primers described above and by measuring miR-33 levels in BM cells by quantitative PCR at age 24 weeks (ie, 16 weeks after BMT).
Quantification of Atherosclerosis
Atherosclerotic lesions were quantified by en face analysis of the whole aorta and by cross-sectional analysis of the proximal aorta. [30] [31] [32] For the en face analysis of the aorta, the Sudan IVstained aortas were photographed and used for the quantification of atherosclerotic lesions. The total aortic surface area and the lesion area were measured by image analysis (ImageJ), and the ratio of the lesion area to the total area was calculated.
For the cross-sectional analysis of the aorta, the OCT-embedded aortas were sectioned using a cryostat, and 6-lm sections were obtained sequentially beginning at the aortic valve. Eight sections obtained every 24 lm from the aortic sinus were stained with oil red O and used for the quantification of lesion areas. The lesion areas of each aorta were measured using ImageJ. The average of the 8 sections from 1 mouse was taken as a value that represented the mouse.
Immunohistochemistry
Eight sections of aortic root per mouse were stained with an anti-CD68 antibody ( 
Apoptosis Assay
After being washed 3 times in PBS, peritoneal macrophages were loaded with free cholesterol (FC) by incubation with RPMI1640 containing 10% FBS supplemented with or without 300 lg/mL of acLDL plus 10 lg/mL of ACAT inhibitor (58035). The next day, cells were assayed for early-to midstage apoptosis by staining with Alexa Fluor 488-conjugated annexin V (green), as described previously 27, 33, 34 , using a Vybrant Apoptosis Assay Kit (Molecular Probes). Representative fields (4 to 6 fields containing %1000 cells) were photographed. The number of annexin V-positive cells was counted and expressed as a percentage of the total number of cells in at least 4 separate fields. For Western blotting of cleaved caspase-3, the samples were collected 48 hours after stimulation.
Measurement of Serum ApoA-I Levels
We quantified serum apoA-I levels in mice using an ELISA assay kit for mouse apoA-I in accordance with the manufacturer's instructions (USCN Life Science Inc, Wuhan, China).
Measurement of Total Cholesterol, Free Cholesterol, Cholesterol Ester, and Triglyceride in the Liver
Lipids in the liver were extracted by the Folch procedure 35 and quantified using standard enzymatic colorimetric methods.
Statistics
Data are presented as mean±SE. Statistical comparisons were performed using nonparametric analysis when the group numbers were <10 (Mann-Whitney U test). Otherwise, unpaired 2-tailed Student t tests were conducted. Statistical significance was tested by a 1-way analysis of variance with the Bonferroni post hoc test when experiments included >2 groups. The level of significance was set at a probability value of <0.05.
Results

MiR-33 Deficiency Reduced Atherosclerosis
To clarify the role of miR-33 in the progression of atherosclerosis, miR-33 À/À mice 22 were mated with Apoe beginning at age 6 weeks, and atherosclerotic lesions were analyzed at age 22 weeks ( Figure 1A ). The atherosclerotic lesion area was examined by an en face analysis of the total aorta and cross-sections of the proximal aorta. The en face analysis of the total aorta showed that atherosclerotic lesions throughout the aorta were significantly reduced in miR-33 Figure 2C and 2D). We also analyzed CD3-positive cells, aSMA-positive area, and picrosirius red staining for collagens ( Figure 3A through 3F Figure 3C and 3D). However, no difference was noted in the collagen area ( Figure 3E and 3F ). There was a significant reduction in lesional apoptosis, as measured by anti-ssDNA staining (P=0.0493; Figure 3G and 3H). These results indicated that a deficiency of miR-33 decreased atherosclerotic plaque size and lipid content and reduced the accumulation of macrophages and T cells in atherosclerotic plaques.
MiR-33 Deficiency Increased HDL-C
We previously reported that miR-33 À/À mice showed 22% to 39% higher serum HDL-C levels than wild-type mice. 22 We measured HDL-C levels in the serum of miR-33 Peritoneal Macrophages From MiR-33
Mice Showed Improved Cholesterol Efflux
To characterize the function of macrophages in cholesterol efflux, thioglycollate-elicited peritoneal macrophages (PEMs) were isolated from mice. Previously, we and others have shown that miR-33 targeted the 3′ untranslated region (UTR) of Abca1 and Abcg1. [16] [17] [18] 22 mRNA expression of ABCA1 and protein expression of ABCA1 and ABCG1 were significantly increased in 
MiR-33 Deficiency Affected Circulating Monocytes and Lesional Macrophages
Our findings thus far indicate that miR-33 deficiency reduced the accumulation of inflammatory cells in atherosclerotic plaque. We then examined whether miR-33 deficiency influenced the monocyte count or subset frequency in peripheral blood. The total leukocyte count in miR-33 À/À Apoe À/À mice was significantly less than that in miR-33 Figure 6A ). Blood monocyte subsets were discriminated by flow cytometry on the basis of their expression of CD115 and Ly6C. 36 The frequency of proinflammatory Ly6C high monocytes in miR-33 À/À Apoe À/À mice was significantly higher than that in miR-33 +/+ Apoe À/À mice ( Figure 6B through 6E).
We further measured iNOS, interleukin (IL)-6, and IL-10 expression in atherosclerotic plaque by immunohistochemistry. As shown in Figure 7A and 7B, the iNOS-positive area in atherosclerotic plaque in miR-33 À/À Apoe À/À mice was significantly less than that in miR-33 +/+ Apoe À/À mice (P=0.0057). On the other hand, no differences were observed in IL-6 and IL-10 immunostaining ( Figure 7C through 7F) . We also characterized miR-33 À/À Apoe À/À macrophages by analyzing the expression of classically activated or proinflammatory (M1) and alternatively activated or anti-inflammatory (M2) macrophage markers using mouse PEMs. A previous article indicated that the inhibition of miR-33 by antisense oligonucleotide enhanced M2 marker expression in macrophages. 19 However, our experiments indicated that the mRNA levels of both M2 markers such as IL-10 and Chi3l3 mRNA and an M1 marker such as IL-6 in PEMs from miR-33
were significantly elevated compared with those from miR-33 Figure 7G ). Overall, these results demonstrate that a loss of miR-33 may have affected multiple pathways in both pro-and anti-inflammatory processes. Moreover, we analyzed adhesion molecule expression by immunostaining. As shown in Figure 8A It has already been shown that miR-33 targets several genes that affect cholesterol and fatty acid synthesis. We measured the mRNA and protein levels of ABCA1, CROT, and CPT1a in the livers of these mice. As shown in Figure 9A through 9C, mRNA of CROT and protein levels of ABCA1 and CROT in miR-33 Figure 9D ). No apparent changes in histology were observed in the livers of these mice, as shown by HE staining ( Figure 9E ). Moreover, we measured the level of RIP140 (NRIP1), which has been shown to be one of the targets of miR-33 in macrophages of these mice. 37 Figure 10A ). Successful hematopoietic reconstitution after BMT was confirmed by PCR amplification of the wholeblood genome 4 weeks after BMT and by PCR amplification of the BM and tail genomes at the time of euthanization. MiR-33 was barely detectable in BM cells from miR-33
recipients by quantitative PCR analysis for miR-33 (data not shown). The serum lipid profile of recipient mice is shown in Table 2 . Serum HDL-C levels of miR-33
ients were the same as those in miR-33
recipients, which were similar to the levels in miR-33 Figure 4A . These results indicated that miR-33 expression in macrophages did not contribute to serum HDL-C levels, which is consistent with the results that the liver and intestine are the major sources of HDL-C.
39,40
MiR-33
Had Reduced Lipid Accumulation in Atherosclerotic Plaque
After mice were fed a WTD for 12 weeks, atherosclerotic lesions in the proximal aortas were measured. Atherosclerotic Figure 10D and 10E). The CD68-positive area is shown in Figure 10F and 10G (P=0.09, 19.5±2.6% versus 26.6±2.6%). These results showed that loss of miR-33 in blood cells reduced the lipid content of atherosclerotic plaque. (Table 2) . Therefore, it was impossible to observe an effect of HDL-C elevation caused by the loss of miR-33 on atherosclerosis in recipients that had the same type of blood cells (Figures 10 and 12 ). 
MiR-33
À/À Apoe À/À Mice Transplanted With MiR-33 À/À Apoe À/À BM Had Reduced Lipid Accumulation in Atherosclerotic Plaque
Discussion
In the current study, miR-33 Apoe À/À macrophages. Together, these data demonstrate that miR-33 deficiency serves to raise HDL-C, improve cholesterol efflux in macrophages, and prevent the progression of atherosclerosis and suggest that miR-33 should be considered as a potential target to prevent the progression of atherosclerosis.
We reported previously that miR-33 À/À in C57/BL6 mice increases HDL-C by up to 40%. MiR-33 À/À Apoe À/À mice also had a higher amount of HDL-C compared with controls. However, the static measurement of HDL-C cholesterol level has inherent limitations as a metric of the functional effects of HDL-C in vivo. Moreover, HDL-C function in Apoe À/À mice may be altered because these mice had no apoE to activate lecithin: cholesterol acyltransferase, which converts free cholesterol to cholesterol ester, thereby creating a gradient for free cholesterol efflux from cells to HDL-C. Thus, we tried to measure the function of HDL-C from miR-33 À/À Apoe À/À mice. Recently, the functionality of HDL-C was analyzed by the quantification of efflux capacity from blood samples of humans. 25 Therefore, we The results of the present BMT experiment revealed that deletion of macrophage miR-33 significantly reduced the lipid content in atherosclerotic plaque. Macrophages are known to ingest apoB-containing lipoproteins and transport ingested lipoprotein-cholesterol from late endosomes to the endoplasmic reticulum (ER) under normal conditions. 41 In advanced lesional macrophages, the accumulation of massive unesterified, or "free," cholesterol is observed, which induces ERstress-mediated macrophage apoptosis. 42 Our results showed that loss of miR-33 in blood cells reduced the lipid content of atherosclerotic plaque, which may be because of improved cholesterol efflux from macrophages. A recent report indicated that the inhibition of miR-33a/b in nonhuman primates raised plasma HDL-C and lowered VLDL triglyceride levels. 47 This result was obtained from the administration of antisense miR-33 for a certain period. These data suggest that it may be possible to inhibit miR-33a and miR-33b pharmacologically to raise HDL-C for the treatment of dyslipidemia and atherosclerosis. However, to establish the safety of this therapeutic strategy for the treatment of humans, the complete inhibition of target miRNA and longerterm assessment in animal disease models are required to avoid unexpected side effects. Moreover, the real targets of miR-33 in vivo can only be clarified by the genetic deletion of miR-33, and the results obtained by antisense oligonucleotide-based medicine may be different from those obtained in miR-33-deficient mice. For example, the administration of miR-21 antagomir prevented pressure-overload-induced cardiac hypertrophy and fibrosis in mice 48 ; however, miR-21-deficient mice did not show any cardiac difference with wild-type mice under pressure overload. 49 There also seems to be a substantial difference in the effect of antisense oligonucleotide against miRNA depending on the modification such as LNA based or cholesterol modified, and many additional miRNAs that share an identical or similar sequence may be inactivated. Therefore, caution is needed when interpreting studies that use antagomir approaches to elucidate the function of individual miRNAs in vivo. Previously, we and others showed that miR-33 targets ABCA1 in macrophages and the liver. ABCG1 is another target seems that only some of these actually have any effect in vivo through the chronic complete inhibition of miRNA. Metabolic syndrome and type 2 diabetes are growing public health concerns worldwide that are associated with complex risk factors for cardiovascular disease (CVD). A previous meta-analysis indicated that a reduction of 2 to 3 mmol/L LDL-C by statins could reduce the risk of CVD by 40% to 50% because there was no evidence of any threshold within the cholesterol range studied. 3 However, this simply means that there is still a substantial risk of CVD despite statins being widely used to lower levels of LDL-C and apolipoprotein B-containing lipoproteins. Major goals in the pursuit of novel therapeutic strategies to target this residual risk have focused on raising the amount and quality of HDL-C to prevent atherosclerosis. Further detailed experiments will be needed to determine whether targeting miR-33 could be a suitable approach for such treatment. 
